TITAN Medical Inc. Appoints Urology Expert Hiep Thieu Nguyen, M.D. to Its Medical Advisory Board

TORONTO, ONTARIO--(Marketwire - October 05, 2010) - Titan Medical Inc. (“the Company”) (TSX VENTURE: TMD) announced today the appointment of Hiep Thieu Nguyen, M.D. to the Company’s Medical Advisory Board.

Currently, Dr. Nguyen is an Associate Professor in Surgery (Urology) at Harvard Medical School and the Director of Robotic Surgery, Research and Training Center at Children’s Hospital, Boston (CHB). Recently, he was named the Rose Zimmerman Mandell Chair in Innovative Urological Technology.

Dr. Nguyen is actively involved in research focusing on vesicoureteral reflux, prenatal hydronephrosis, molecular imaging, and robotics/minimally invasive surgery. In the area of robotic surgery, he is investigating the application of this minimally invasive technique to reconstruction of the urinary tract and its safety. He is also collaborating with colleagues at CHB to design hand-held robotic instruments for the US Army. In addition, due to his strong background in basic science, he is working to apply molecular imaging technology to be used in laparoscopic and endoscopic surgery.

Craig Leon, Chairman and CEO of Titan Medical, commented, “Dr. Nguyen’s credibility and extensive expertise in minimally invasive surgeries, as well as his active clinical practice in urology, ideally position him to provide strategic medical advice for our research and development program. We believe that having him on our scientific advisory board will enable us to advance our Amadeus system from the development stage to human trials in an effective and timely manner.”

Hiep Thieu Nguyen added, “Amadeus is truly a breakthrough technology that has the potential to change the way robotics surgeries are done. I am excited to be affiliated with Titan and look forward to contributing my skills toward advancing this technology for urological procedures.”

Dr. Nguyen received his medical degree and completed his Surgery and Urology residency at the University of California, San Francisco. He also completed a fellowship in Pediatric Urology at CHB. Dr. Nguyen is an active member in the American Academy of Pediatrics, Section in Urology, the Society for Pediatric Urology, the Society for Fetal Urology, the American Urological Association and International Volunteers in Urology.

About Titan Medical Inc.

Titan Medical Inc. is a Canadian public company (TSX VENTURE: TMD) focused on the development and commercialization of robotic surgical technologies. The Company is currently developing Amadeus, a next generation 4-armed robotic surgical system, with the objective of enabling surgeons to remotely manipulate surgical instruments. Robotic surgery has developed over the past 10 years into a proven and growing method of treatment. The current global robotic surgical market size is approximately $1 billion and is estimated to grow to $5 billion by 2015 with potential for placement of 6,000 robotic surgical systems. The Company is researching and developing innovative technologies to empower surgeons to use robots in the operating room of the future. For more information, visit the Company’s website at www.titanmedicalinc.com.

Forward Looking Statements

This news release contains “forward-looking statements” which reflect the current expectations of management of the Company’s future growth, results of operations, performance and business prospects and opportunities. Wherever possible, words such as “may”, “would”, “could”, “will”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate” and similar expressions have been used to identify these forward-looking statements. These statements reflect management’s current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, without limitation, those listed in the “Risk Factors” section of the Company’s Annual Information Form dated April 9, 2010 (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.